Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Medtronic
McKinsey
Harvard Business School

Last Updated: August 15, 2022

Investigational Drug Information for Fluoropyrimidine


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Fluoropyrimidine?

Fluoropyrimidine is an investigational drug.

There have been 279 clinical trials for Fluoropyrimidine. The most recent clinical trial was a Phase 3 trial, which was initiated on July 30th 2018.

The most common disease conditions in clinical trials are Colorectal Neoplasms, Stomach Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Eli Lilly and Company, and Hoffmann-La Roche.

There are nine hundred and twenty-one US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Fluoropyrimidine
TitleSponsorPhase
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction TherapyCRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San MartinoPhase 2
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction TherapyLaboratory Molecular Oncology Candiolo Cancer Institute IRCCS - Candiolo (Torino)Phase 2
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction TherapyOspedale Policlinico San MartinoPhase 2

See all Fluoropyrimidine clinical trials

Clinical Trial Summary for Fluoropyrimidine

Top disease conditions for Fluoropyrimidine
Top clinical trial sponsors for Fluoropyrimidine

See all Fluoropyrimidine clinical trials

US Patents for Fluoropyrimidine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fluoropyrimidine See Plans and Pricing Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) See Plans and Pricing
Fluoropyrimidine See Plans and Pricing Combination therapies for cancer MERCK SHARP & DOHME CORP. (Rahway, NJ) NOVARTIS AG (Basel, CH) See Plans and Pricing
Fluoropyrimidine See Plans and Pricing Tapered looped suture Covidien LP (Mansfield, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fluoropyrimidine

Drugname Country Document Number Estimated Expiration Related US Patent
Fluoropyrimidine World Intellectual Property Organization (WIPO) WO2013071079 2031-11-09 See Plans and Pricing
Fluoropyrimidine European Patent Office EP3003316 2033-05-31 See Plans and Pricing
Fluoropyrimidine Spain ES2822665 2033-05-31 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Medtronic
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.